614 related articles for article (PubMed ID: 34012082)
1. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates.
Musunuru K; Chadwick AC; Mizoguchi T; Garcia SP; DeNizio JE; Reiss CW; Wang K; Iyer S; Dutta C; Clendaniel V; Amaonye M; Beach A; Berth K; Biswas S; Braun MC; Chen HM; Colace TV; Ganey JD; Gangopadhyay SA; Garrity R; Kasiewicz LN; Lavoie J; Madsen JA; Matsumoto Y; Mazzola AM; Nasrullah YS; Nneji J; Ren H; Sanjeev A; Shay M; Stahley MR; Fan SHY; Tam YK; Gaudelli NM; Ciaramella G; Stolz LE; Malyala P; Cheng CJ; Rajeev KG; Rohde E; Bellinger AM; Kathiresan S
Nature; 2021 May; 593(7859):429-434. PubMed ID: 34012082
[TBL] [Abstract][Full Text] [Related]
2. In Vivo Base Editing of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) as a Therapeutic Alternative to Genome Editing.
Chadwick AC; Wang X; Musunuru K
Arterioscler Thromb Vasc Biol; 2017 Sep; 37(9):1741-1747. PubMed ID: 28751571
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of an Investigational Single-Course CRISPR Base-Editing Therapy Targeting
Lee RG; Mazzola AM; Braun MC; Platt C; Vafai SB; Kathiresan S; Rohde E; Bellinger AM; Khera AV
Circulation; 2023 Jan; 147(3):242-253. PubMed ID: 36314243
[TBL] [Abstract][Full Text] [Related]
4. In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels.
Rothgangl T; Dennis MK; Lin PJC; Oka R; Witzigmann D; Villiger L; Qi W; Hruzova M; Kissling L; Lenggenhager D; Borrelli C; Egli S; Frey N; Bakker N; Walker JA; Kadina AP; Victorov DV; Pacesa M; Kreutzer S; Kontarakis Z; Moor A; Jinek M; Weissman D; Stoffel M; van Boxtel R; Holden K; Pardi N; Thöny B; Häberle J; Tam YK; Semple SC; Schwank G
Nat Biotechnol; 2021 Aug; 39(8):949-957. PubMed ID: 34012094
[TBL] [Abstract][Full Text] [Related]
5. Long-term stable reduction of low-density lipoprotein in nonhuman primates following in vivo genome editing of PCSK9.
Wang L; Breton C; Warzecha CC; Bell P; Yan H; He Z; White J; Zhu Y; Li M; Buza EL; Jantz D; Wilson JM
Mol Ther; 2021 Jun; 29(6):2019-2029. PubMed ID: 33609733
[TBL] [Abstract][Full Text] [Related]
6. Programmable Genome-Editing Technologies as Single-Course Therapeutics for Atherosclerotic Cardiovascular Disease.
Jindal I; Wang X
Curr Atheroscler Rep; 2022 Nov; 24(11):861-866. PubMed ID: 35994136
[TBL] [Abstract][Full Text] [Related]
7. Gene Editing for the Treatment of Hypercholesterolemia.
Hoekstra M; Van Eck M
Curr Atheroscler Rep; 2024 May; 26(5):139-146. PubMed ID: 38498115
[TBL] [Abstract][Full Text] [Related]
8. CRISPR-Cas9 Targeting of PCSK9 in Human Hepatocytes In Vivo-Brief Report.
Wang X; Raghavan A; Chen T; Qiao L; Zhang Y; Ding Q; Musunuru K
Arterioscler Thromb Vasc Biol; 2016 May; 36(5):783-6. PubMed ID: 26941020
[TBL] [Abstract][Full Text] [Related]
9. Triple-Targeting Delivery of CRISPR/Cas9 To Reduce the Risk of Cardiovascular Diseases.
Zhang L; Wang L; Xie Y; Wang P; Deng S; Qin A; Zhang J; Yu X; Zheng W; Jiang X
Angew Chem Int Ed Engl; 2019 Sep; 58(36):12404-12408. PubMed ID: 31318118
[TBL] [Abstract][Full Text] [Related]
10. CRISPR base editing lowers cholesterol in monkeys.
van Kampen SJ; van Rooij E
Nat Biotechnol; 2021 Aug; 39(8):920-921. PubMed ID: 34168346
[No Abstract] [Full Text] [Related]
11. CES1-Triggered Liver-Specific Cargo Release of CRISPR/Cas9 Elements by Cationic Triadic Copolymeric Nanoparticles Targeting Gene Editing of PCSK9 for Hyperlipidemia Amelioration.
Zhao Y; Li Y; Wang F; Gan X; Zheng T; Chen M; Wei L; Chen J; Yu C
Adv Sci (Weinh); 2023 Jul; 10(19):e2300502. PubMed ID: 37083231
[TBL] [Abstract][Full Text] [Related]
12. In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model.
Carreras A; Pane LS; Nitsch R; Madeyski-Bengtson K; Porritt M; Akcakaya P; Taheri-Ghahfarokhi A; Ericson E; Bjursell M; Perez-Alcazar M; Seeliger F; Althage M; Knöll R; Hicks R; Mayr LM; Perkins R; Lindén D; Borén J; Bohlooly-Y M; Maresca M
BMC Biol; 2019 Jan; 17(1):4. PubMed ID: 30646909
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Dyslipidemia Using CRISPR/Cas9 Genome Editing.
Chadwick AC; Musunuru K
Curr Atheroscler Rep; 2017 Jul; 19(7):32. PubMed ID: 28550381
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic application of genome editing in dyslipidemia.
Whittaker MN; Musunuru K
Curr Opin Lipidol; 2022 Apr; 33(2):133-138. PubMed ID: 34907967
[TBL] [Abstract][Full Text] [Related]
15. Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol.
Xu YX; Redon V; Yu H; Querbes W; Pirruccello J; Liebow A; Deik A; Trindade K; Wang X; Musunuru K; Clish CB; Cowan C; Fizgerald K; Rader D; Kathiresan S
Atherosclerosis; 2018 Jan; 268():196-206. PubMed ID: 29183623
[TBL] [Abstract][Full Text] [Related]
16. Rewriting DNA in the body lowers cholesterol.
Kaiser J
Science; 2023 Nov; 382(6672):751. PubMed ID: 37972155
[TBL] [Abstract][Full Text] [Related]
17.
Wagner J; Bell AS; Lohoff FW
ACS Chem Neurosci; 2022 Dec; 13(23):3210-3212. PubMed ID: 36374568
[TBL] [Abstract][Full Text] [Related]
18. Gene Therapy Targeting
Katzmann JL; Cupido AJ; Laufs U
Metabolites; 2022 Jan; 12(1):. PubMed ID: 35050192
[TBL] [Abstract][Full Text] [Related]
19. Meganuclease targeting of PCSK9 in macaque liver leads to stable reduction in serum cholesterol.
Wang L; Smith J; Breton C; Clark P; Zhang J; Ying L; Che Y; Lape J; Bell P; Calcedo R; Buza EL; Saveliev A; Bartsevich VV; He Z; White J; Li M; Jantz D; Wilson JM
Nat Biotechnol; 2018 Sep; 36(8):717-725. PubMed ID: 29985478
[TBL] [Abstract][Full Text] [Related]
20. Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates.
Liang H; Chaparro-Riggers J; Strop P; Geng T; Sutton JE; Tsai D; Bai L; Abdiche Y; Dilley J; Yu J; Wu S; Chin SM; Lee NA; Rossi A; Lin JC; Rajpal A; Pons J; Shelton DL
J Pharmacol Exp Ther; 2012 Feb; 340(2):228-36. PubMed ID: 22019884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
